Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: A systematic comparison of predictions from four mathematical models

The Lancet

Volumn 387, Issue 10016, 2016, Pages 367-375

  Penny, Melissa A ^a,b   Verity, Robert ^c   Bever, Caitlin A ^d   Sauboin, Christophe ^e   Galactionova, Katya ^a,b   Flasche, Stefan ^f   White, Michael T ^c   Wenger, Edward A ^d   Van De Velde, Nicolas ^e   Pemberton Ross, Peter ^a,b   Griffin, Jamie T ^c   Smith, Thomas A ^a,b   Eckhoff, Philip A ^d   Muhib, Farzana ^g   Jit, Mark ^f,h   Ghani, Azra C ^c  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d INSTITUTE FOR DISEASE MODELING   (United States)

^e GSK   (Belgium)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g PATH   (United States)

^h PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

AFRICA; ARTICLE; COST EFFECTIVENESS ANALYSIS; FINANCIAL MANAGEMENT; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HUMAN; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MATHEMATICAL MODEL; PARASITE PREVALENCE; PHASE 3 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PREDICTIVE VALUE; PRIORITY JOURNAL; PUBLIC HEALTH; COST BENEFIT ANALYSIS; ECONOMICS; IMMUNIZATION; INFANT; MALARIA, FALCIPARUM; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); THEORETICAL MODEL;

AFRICA; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MODELS, THEORETICAL; MULTICENTER STUDIES AS TOPIC; PUBLIC HEALTH;

EID: 84959529896     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00725-4     Document Type: Article

References (30)

1. WHO World malaria report 2013 2014 World Health Organization Geneva
2. S Bhatt, DJ Weiss, E Cameron et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015 Nature 526 2015 207 211
3. RTSS Clinical Trials Partnership Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial Lancet 386 2015 31 45
4. AP Patil, EA Okiro, PW Gething et al. Defining the relationship between Plasmodium falciparum parasite rate and clinical disease: statistical models for disease burden estimation Malar J 8 2009 186
5. Hamel MJ, Oneko M, Williamson J. A marked reduction in mortality among participants in a clinical trial that removed barriers to care and implemented national case management guidelines. 63rd Annual meeting of the American Society of Tropical Medicine and Hygiene; New Orleans, LA; Nov 2-6, 2014. 631 (abstr).
6. R Hutubessy, AM Henao, P Namgyal, V Moorthy, J Hombach Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal BMC Med 9 2011 55
7. VS Moorthy, R Hutubessy, RD Newman, J Hombach Decision-making on malaria vaccine introduction: the role of cost-effectiveness analyses Bull World Health Organ 90 2012 864 866
8. LA Lee, L Franzel, J Atwell et al. The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance Vaccine 31 2013 B61 B72
9. KA McCarthy, EA Wenger, GH Huynh, PA Eckhoff Calibration of an intrahost malaria model and parameter ensemble evaluation of a pre-erythrocytic vaccine Malar J 14 2015 6
10. Sauboin C, Van Vlaenderen I, Van Bellinghen LA, Standaert B. Cost-effectiveness of RTS,S malaria vaccine candidate in children estimated using a Markov cohort model and phase 3 trial results. 3rd International Conference of the African Health Economics and Policy Association; Nairobi, Kenya; March 11-13, 2014. 40 (abstr).
11. JT Griffin, NM Ferguson, AC Ghani Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa Nat Commun 5 2014 3136
12. T Smith, A Ross, N Maire et al. Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine PLoS Med 9 2012 44
13. MA Penny, K Galactionova, M Tarantino, M Tanner, TA Smith The public health impact of malaria vaccine RTS, S in malaria endemic Africa: country-specific predictions using 18 month follow-up phase III data and simulation models BMC Med 13 2015 170
14. MT White, R Verity, JT Griffin et al. Immunogenicity of the RTS,S/AS01 malaria vaccine over time and implications for duration of vaccine efficacy: analysis of data from a phase 3 randomised controlled trial Lancet Infect Dis 2015 published online Sept 2. http://dx.doi.org:10.1016/S1473-3099(15)00239-X
15. INDEPTH Network Model life tables for sub-Saharan Africa 2004 Ashgate Publishing Aldershot
16. WHO WHO-UNICEF estimates of DTP3 coverage. 2013 http://apps.who.int/immunization-monitoring/globalsummary/timeseries/tswucoveragedtp3.html (accessed Dec 1, 2014).
17. World Health Organization Global technical strategy for malaria 2016-2030 2015 World Health Organization Geneva
18. The RTSS Clinical Trials Partnership Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African Sites PLoS Med 11 2014 e1001685
19. BM Greenwood, PH David, LN Otoo-Forbes et al. Mortality and morbidity from malaria after stopping malaria chemoprophylaxis Trans R Soc Trop Med Hyg 89 1995 629 633
20. JJ Aponte, C Menendez, D Schellenberg et al. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation PLoS Med 4 2007 e242
21. RD Gosling, AC Ghani, JL Deen, L von Seidlein, BM Greenwood, D Chandramohan Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? Malar J 7 2008 54
22. WHO UN Children's Fund Achieving the malaria MDG target: reversing the incidence of malaria 2000-2015 2015 World Health Organization Geneva
23. K Marsh, R Snow Malaria transmission and morbidity Parassitologia 41 1999 241 246
24. A Olotu, G Fegan, J Wambua et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure N Engl J Med 368 2013 1111 1120
25. MT White, L Conteh, R Cibulskis, AC Ghani Costs and cost-effectiveness of malaria control interventions - a systematic review Malar J 10 2011 337
26. JO Yukich, C Lengeler, F Tediosi et al. Costs and consequences of large-scale vector control for malaria Malar J 7 2008 258
27. C Lengeler Insecticide-treated bed nets and curtains for preventing malaria Cochrane Database Syst Rev 2 2004 CD000363.
28. MT White, JT Griffin, O Akpogheneta et al. Dynamics of the antibody response to Plasmodium falciparum infection in African children J Infect Dis 210 2014 1115 1122
29. WHO WHO guide for standardization of economic evaluations of immunization programmes 2008 World Health Organization Geneva
30. WHO Global Advisory Committee on Vaccine Safety, 11-12 June 2014 Wkly Epidemiol Rec 89 2014 325 335